VANGUARD GROUP INC 13D and 13G filings for Theravance Biopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 5:53 pm Unchanged | 2024-09-30 | 13G | Theravance Biopharma, Inc. TBPH | VANGUARD GROUP INC | 2,051,689 4.190% | 0 (Unchanged) | Filing |
| 2024-11-04 3:33 pm Unchanged | 2024-09-30 | 13G | Theravance Biopharma, Inc. TBPH | VANGUARD GROUP INC | 2,051,689 4.190% | 0 (Unchanged) | Filing |
| 2024-11-04 2:10 pm Sale | 2024-09-30 | 13G | Theravance Biopharma, Inc. TBPH | VANGUARD GROUP INC | 2,051,689 4.190% | -1,437,573 (-41.20%) | Filing |
| 2024-02-13 5:15 pm Sale | 2023-12-29 | 13G | Theravance Biopharma, Inc. TBPH | VANGUARD GROUP INC | 3,489,262 7.010% | -2,069,577 (-37.23%) | Filing |
| 2023-02-09 11:35 am Sale | 2022-12-30 | 13G | Theravance Biopharma, Inc. TBPH | VANGUARD GROUP INC | 5,558,839 8.250% | -740,984 (-11.76%) | Filing |
| 2022-02-10 08:42 am Purchase | 2021-12-31 | 13G | Theravance Biopharma, Inc. TBPH | VANGUARD GROUP INC | 6,299,823 8.550% | 1,645,514 (+35.35%) | Filing |
| 2021-02-10 11:57 am Purchase | 2020-12-31 | 13G | Theravance Biopharma, Inc. TBPH | VANGUARD GROUP INC | 4,654,309 7.270% | 650,707 (+16.25%) | Filing |
| 2020-02-12 11:08 am Purchase | 2019-12-31 | 13G | Theravance Biopharma, Inc. TBPH | VANGUARD GROUP INC | 4,003,602 7.050% | 23,542 (+0.59%) | Filing |